If the Fed Cuts Again, IEFA Could Rally Further. Here’s Your Monitoring Checklist.

The iShares Core MSCI EAFE ETF (NYSEARCA:IEFA) has quietly become one of the best-performing core holdings in U.S. investor portfolios this year, climbing roughly 10.5% year to date and roughly 24% over the past 12 months to around $97. With 7 basis points in fees and roughly 2,500 developed-market holdings across Europe, Japan, and Australia, IEFA is the cheapest mainstream way to own ex-U.S. developed equities. The question heading into the second half of 2026 is whether the rally has legs or whether the two engines driving it are running out of fuel.

What IEFA actually owns right now

IEFA tracks the MSCI EAFE IMI index, so it skews toward European and Japanese megacaps. The top of the book is dominated by ASML at 2.12%, followed by a wall of European healthcare and consumer staples: AstraZeneca at 1.27%, Novartis at 1.21%, Roche at 1.17%, and Nestle at 1.07%. Banks (HSBC, Commonwealth Bank of Australia) and energy (Shell, TotalEnergies) round out the top ten. That mix matters because it tells you what IEFA is really sensitive to: the euro and pound versus the dollar, European drug pricing, and the global semiconductor capex cycle.

The macro factor that matters most: the dollar, driven by the Fed

The single biggest swing factor for IEFA over the next 12 months is the U.S. dollar, and the Fed is the lever. The Federal Reserve has already cut 75 basis points since September 2025, taking the upper bound to 3.75%, and has held there for six months. Roughly half of IEFA’s 2026 gain has come from currency translation as the dollar softened against the euro and yen. JP Morgan’s 2026 outlook flags that the U.S. dollar is still about 10% overvalued versus fair value, which leaves room for further weakness if cuts continue.

What to watch concretely: the CME FedWatch tool for the September and December 2026 meetings, and the next dot plot. If FedWatch keeps pricing two or more additional cuts this year, IEFA’s tailwind continues. If the 10-year Treasury yield, currently around 4.5% and near the upper end of its 12-month range, breaks back above 4.7%, that would likely flip the dollar higher and clip 3% to 5% off IEFA’s unhedged return over a quarter. Check monthly; act on the FOMC release dates.

The fund-specific factor: ASML and the European pharma cluster

Inside the portfolio, the concentration risk is thematic. ASML alone moves IEFA more than any other single name, and the three large European drugmakers (AstraZeneca, Novartis, Roche) together account for roughly roughly 4% of net assets. ASML’s quarterly bookings, reported every January, April, July, and October, are the most important fund-specific data release for IEFA. A soft order quarter or a guide-down on 2027 EUV demand would hit the fund disproportionately, since ASML has been the single largest contributor to EAFE earnings revisions for two years.

Investors who want similar geographic exposure but less single-stock risk can look at the iShares Currency Hedged MSCI EAFE ETF (NYSEARCA:HEFA), the currency-hedged sibling, which strips out the dollar swing factor. If your view is that the dollar has bottomed, HEFA is the right vehicle. If you think Fed cuts will keep coming, IEFA is.

The bottom line for the next 12 months

Track the September FOMC decision and ASML’s July earnings release. A dovish Fed plus an ASML order beat extends the rally. A hawkish hold and a semi-capex pause is the combination that ends it.